ReviewDrugs & aging2005
The impact of age on rejection in kidney transplantation.
Review in Drugs & aging, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 60 citations in OpenAlex.
- A Comprehensive Assessment of Plasma CXCL9 and CXCL10 in Improving Clinical Prediction Models for Kidney Allograft Rejection.Clinical transplantation · 2025Article
- Impact of Immunosenescence in Older Kidney Transplant Recipients: Associated Clinical Outcomes and Possible Risk Stratification for Immunosuppression Reduction.Drugs & aging · 2024Review
- NK Cells Contribute to the Immune Risk Profile in Kidney Transplant Candidates.Frontiers in immunology · 2019Article
- Amniotic fluid cells: current progress and emerging challenges in renal regeneration.Pediatric nephrology (Berlin, Germany) · 2018Review
- Tissue conservation for transplantation.Innovative surgical sciences · 2017Review
- Aging and the immune response to organ transplantation.The Journal of clinical investigation · 2017Review
- Longitudinal analysis of whole blood transcriptomes to explore molecular signatures associated with acute renal allograft rejection.Bioinformatics and biology insights · 2014Article
- Renal allograft nephrectomy: comparison between clinical and pathological diagnosis.Nephro-urology monthly · 2013Article
- Enhanced significance of donor-recipient age gradient as a prognostic factor of graft outcome in living donor kidney transplantation.World journal of surgery · 2013Article
- Renal transplantation from elderly living donors.Journal of transplantation · 2013Review
- Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2012Article
- Aging and transplantation - a topic for biomedicine or bioethics?Aging and disease · 2011Article
- [Ten years of the Eurotransplant senior program : are there still age limits for kidney transplantation?].Der Urologe. Ausg. A · 2009Article
- Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions.Drugs & aging · 2009Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The time to failure of a renal allograft is determined by the initial function achieved after transplantation, the number and severity of insults to the graft, and a number of tissue characteristics. The insults a graft usually encounters include ischaemia/reperfusion injury, acute rejection episodes, drug-related nephrotoxicity, hypertension and hyperlipidaemia. Important tissue characteristics include susceptibility to injury and the ability of the tissue to repair damage. Elderly transplant recipients are considered poor immune responders but if a single acute rejection episode occurs this is more likely to significantly shorten graft and patient survival in this age group. Two issues have been identified with the use of old (>50 years of age) donor kidneys. First, compared with kidneys from younger donors, they have an increased incidence of acute interstitial rejection. Secondly, once a rejection episode occurs, the ability to mount a tissue repair process seems impaired. An explanation for the increased loss of grafts from old donors that have experienced acute rejection episodes is that such kidneys have fewer nephrons that function adequately and that the cumulated effect of damage results in an earlier demise of the graft compared with younger donor kidneys. Alternatively, graft parenchymal cells may undergo premature senescence or aging as a result of multiple injuries and repair. If progressive loss of renal mass or senescence is the mechanism responsible for increased graft loss, then it is expected that grafts from older donors will show a progressive decrease in function over time and that the rate of decline of function will correlate with donor age. We have suggested that increased graft loss of older donor kidneys results from increased incidence of acute rejection episodes in the early post-transplantation months together with a partly impaired ability to repair the tissue. Drug pharmacokinetic parameters are generally little influenced by age. However, the degree to which drugs suppress the immune system, and the extent to which kidneys from older donors are susceptible to the nephrotoxic effects of certain drugs, are unpredictable. There appears to be a more delicate balance between adequate immunosuppression and excess nonimmune toxicity in patients receiving older kidneys. Outcome parameters in elderly renal transplant recipients are currently dominated by increased death from infectious disease and drug-related (cardiovascular) causes. Increased susceptibility to nephrotoxic drugs, and to calcineurin inhibitors in particular, may be related to the increased risk of allograft failure experienced by the elderly as a surrogate for chronic allograft nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.